Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
November 29 2023 - 7:03AM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or
“Unicycive”), a clinical-stage biotechnology company developing
therapies for patients with kidney disease, today announced that
Shalabh Gupta, M.D., Chief Executive Officer will participate in
two upcoming investor conferences in December 2023.
Noble Capital Markets 19th Annual
Emerging Growth Equity Conference
(NobleCon)Presentation: Monday, December 4, 2023
at 3:30 pm ET Boca Raton, FLA
high-definition video webcast of the presentation will be available
the following day on the Unicycive website under the Investors
section: Events and Presentations.
2023 Benchmark Discovery One-on-One
Investor ConferenceDecember 7,
2023New York, NY
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases.
Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a
novel investigational phosphate binding agent being developed for
the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis. UNI-494 is a patent-protected new chemical
entity in late preclinical development for the treatment of acute
kidney injury. For more information, please visit
Unicycive.com and follow us on LinkedIn and YouTube.
Investor Contact:
ir@unicycive.com(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From Apr 2024 to May 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From May 2023 to May 2024